VKTX is forecast to increase its losses from $0.91 per share in 2023 to $1.12 per share in 2024, and again to $1.47 per share in 2025. Given its current outstanding share count, its losses in the next two years will range around $220 million. Viking Therapeutics ended 2023 with more than $360 million in cash, providing it with enough room to sustain its cash burn rates for the next three years.